Overview ( 160 members taking Copegus )
This product is used in combination with peginterferon alfa-2a (Pegaysys) for the treatment of chronic Hepatitis C. Its exact mechanism of action is unknown.
This product has a black box warning related to its risk of causing anemia, worsening heart disease, and its lack of effectiveness when used alone. Both female patients taking ribavirin and female partners of male patients taking ribavirin should avoid pregnancy during therapy and for 6 months after completing therapy.
What is your Risk Rating for this medicine?
The risk of serious side effects for taking this medicine can be different if you take other medicines or if you suffer from a condition. Get your Risk Rating by creating a profile in a few steps.
- We monitor your health and alert you to any safety updates and recalls.
- You get to talk directly to other members about their experience.
- You can create profiles for you and your loved ones.
We check for possible drug-drug or drug-condition interactions for your medical treatment so you know when there is an issue. Drug interactions may create serious side effects that you want to discuss with your doctor.Register to check interactions